Fixed-Duration Therapy Shows promise in Chronic Lymphocytic Leukemia Treatment
Table of Contents
A new analysis of data from the CLL-17 trial suggests that fixed-duration therapies for chronic lymphocytic leukemia (CLL) can achieve similar outcomes to continuous treatment, while potentially mitigating long-term side effects and financial burdens. The findings, presented at the ASH Annual Meeting and Exposition in Orlando on December 6-9, 2025, reveal comparable 3-year progression-free survival rates between continuous bruton tyrosine kinase (BTK) inhibitor monotherapy with ibrutinib and fixed-duration regimens combining venetoclax plus obinutuzumab, or venetoclax plus ibrutinib.
Balancing Efficacy and Tolerability in CLL Treatment
For patients newly diagnosed with CLL, treatment options have traditionally included continuous therapies, such as ibrutinib. However, these approaches can be associated with prolonged exposure to side effects and significant costs. The CLL-17 trial data offers a potential solution by demonstrating that fixed-duration therapies can deliver comparable efficacy without the same drawbacks.
“the key takeaway is that the long-term side effects of continuous BTK inhibitor therapy, and also the financial toxicity that comes with that, can be overcome by using these fixed-duration therapies,” explained a hematology/oncology expert from Fox Chase Cancer Center. “This is exciting data.”
CLL-17 Trial Details and Findings
The research compared the effectiveness of continuous ibrutinib monotherapy to fixed-duration combinations involving venetoclax. The 3-year progression-free survival rates were similar across all treatment arms, indicating that patients can achieve sustained remission with both approaches. This is especially significant as it opens the door to reducing treatment duration and potentially improving patients’ quality of life.
The expert emphasized that the ability to avoid the long-term toxicities associated with continuous BTK inhibitor therapy is a major advantage. Furthermore, the reduced financial burden associated with shorter treatment courses could improve access to care for a wider range of patients.
Expert Insights and Future directions
The findings from the CLL-17 trial represent a significant step forward in the management of CLL. Researchers are continuing to investigate the optimal duration of therapy and identify biomarkers that can predict which patients are most likely to benefit from fixed-duration regimen
Why: Researchers sought to determine if fixed-duration CLL therapies could match the effectiveness of continuous treatment while reducing long-term side effects and costs.
Who: the study involved patients with newly diagnosed CLL, and the findings were presented by researchers at the ASH Annual Meeting and Exposition. A hematology/oncology expert from Fox Chase Cancer Center provided commentary.
what: The CLL-17 trial data showed comparable 3-year progression-free survival rates between continuous ibrutinib and fixed-duration regimens of venetoclax combinations.
How did it end?: The trial concluded that fixed-duration therapies are a viable option to continuous treatment, offering potential benefits in terms of tolerability and cost. Researchers are now focused on optimizing treatment duration and identifying biomarkers to personalize therapy.
Source: Healio Interviews
Reference: Al-Sawaf O, et al. Abstract 1. Presented at: ASH Annual Meeting and exposition; Dec.6-9, 2025; Orlando.
Disclosures: nakhoda reports receiving research funding from Serb Pharmaceuticals and receives honoraria and research support from AstraZeneca, BeOne Medicines and Genentech.
